Anemia and chronic heart failure: Are we asking the right questions?

Circulation

Volumn 112, Issue 12, 2005, Pages 1681-1683

  Clark, Andrew L ^a   Cleland, John G F ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Anemia; Angiotensin; Editorials; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SERASPENIDE;

ANEMIA; BLOOD VISCOSITY; EDITORIAL; ERYTHROPOIESIS; HEART FAILURE; HEART FUNCTION; HEMATOCRIT; HEMATOPOIESIS; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

ANEMIA; CHRONIC DISEASE; ERYTHROCYTE COUNT; ERYTHROPOIESIS; HEART FAILURE, CONGESTIVE; HEMATOCRIT; HUMANS; MODELS, BIOLOGICAL;

EID: 25444458841     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.576181     Document Type: Editorial

References (29)

1. Cleland JG, Clark AL. Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth. J Am Coll Cardiol. 2003;42:1234-1237.
2. Cleland JG, Coletta AP, Freemantle N, Velavan P, Tin L, Clark AL. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HP, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail. 2005;7:931-936.
3. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
4. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail. 2002;8:124-127.
5. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352: 1539-1549.
6. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-930.
7. van der Meer P, Lipsic E, Daan Westenbrink BD, van de Wal RMA, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743-1747.
8. Cleland JG, Coletta AP, Clark AL, Velavan P, Ingle L. Clinical trials update from the European Society of Cardiology heart failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS and ASCOT-BPLA. Eur J Heart Fail. 2005;7:937-939.
9. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
10. Komajda M, Cleland J, DiLenarda A, Metra M, Remme W, Swedberg K, Lutiger B, Poole-Wilson P; COMET Investigators. Clinical profile and outcome of anaemic patients with chronic heart failure in the COMET trial. Eur Heart J. 2005;25:S651.
11. Androne AS, Hryniewicz K, Hudaihed A, Mancini D, Lamanca J, Katz SD. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004;93:1254-1259.
12. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16:87-96.
13. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930-933.
14. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22.
15. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J. 1994;127:607-612.
16. Julian BA, Brantley RR, Barker CV, Stopka T, Gaston RS, Curtis JJ, Lee JJ. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol. 1998;9: 1104-1108.
17. Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT antagonists. Eur J Heart Fail. 2000;2:393-398.
18. Cleland JG, Gillen G, Dargie HJ. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J. 1988;9:132-141.
19. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospital-izations. J Am Coll Cardiol. 2000;35:1737-1744.
20. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
21. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538-548.
22. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, Sheps D, Keren G. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med. 2005;165:1304-1309.
23. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293: 1900-1905.
24. Grillon C, Rieger K, Bakala J, Schott D, Morgat JL, Hannappel E, Voelter W, Lenfant M. Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Lett. 1990;274:30-34.
25. Huff T, Otto AM, Muller CS, Meier M, Hannappel E. Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J. 2002;16:691-696.
26. Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, Ithakissios DS, Evangelatos GP. Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta. 2001;1568:60-66.
27. Jackson JD, Yan Y, Ewel C, Talmage JE. Activity of Acetyl-Ser-Asp-Lys-Pro (AcSDKP) on hematopoietic progenitors in short-term and long-term murine bone marrow cultures. Exp Hematol. 1996;24: 475-481.
28. Guigon M, Bonnet D, Lemoine F, Kobari L, Parmentier C, Mary JY, Najman A. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Exp Hematol. 1995;18:1112-1115.
29. Cingolani OH, Yang XP, Liu YH, Villanueva M, Rhaleb NE, Carretero OA. Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats. Hypertension. 2004;43: 1067-1073.